Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

Wouters, E. F. M.; Postma, D. S.; Fokkens, B.; Hop, W. C. J.; Prins, J.; Kuipers, A. F.; Pasma, H. R.; Hensing, C. A. J.; Creutzberg, E. C.
June 2005
Thorax;Jun2005, Vol. 60 Issue 6, p480
Academic Journal
Background: Guidelines recommend inhaled corticosteroids (ICS) as maintenance treatment for patients with chronic obstructive pulmonary disease (COPD) with a post-bronchodilator forced expiratory volume in 1 second (FEV1) <50% predicted and frequent exacerbations, although they have only a small preventive effect on the accelerated decline in lung function. Combined treatment with ICS and long acting 132 agonists (LABA) may provide benefit to the stability of COPD, but it is unknown if withdrawal of CS will result in disease deterioration. Methods: The effects of 1 year withdrawal of the ICS fluticasone propionate (FP) after a 3 month run-in treatment period with FP combined with the LABA salmeterol (S) (500 μg FP +50 μg S twice daily; SFC) were investigated in patients with COPD in a randomised, double blind study. 497 patients were enrolled from 39 centres throughout the Netherlands; 373 were randomised and 293 completed the study. Results: The drop out rate after randomisation was similar in the two groups. Withdrawal of FR resulted in a sustained decrease in FEV1: mean (SE) change from baseline -4.4 (0.9)% (S) v -0.1 (0.9)% (SFC); adjusted difference 4.1 (95% CI 1.6 to 6.6) percentage points (p<0.001). Corresponding figures for the FEV1/FVC ratio were -3.7 (0.8)% (5) v 0.0 (0.8)% (SFC) (p=0.002). The annual moderate to severe exacerbation rate was 1.6 and 1.3 in the S and SFC groups, respectively (adjusted rate ratio 1.2; 95% CI 0.9 to 1.5; p =0.15). The mean annual incidence rate of mild exacerbations was 1.3 (5) v 0.6 (SFC), p =0.020. An immediate and sustained increase in dyspnoea score (scale 0-4; mean difference between groups 0.17 (0.04), p<0.001) and in the percentage of disturbed nights (6 (2) percentage points, p<0.001) occurred after withdrawal of fluticasone. Conclusions: Withdrawal of FP in COPD patients using SFC resulted in acute and persistent deterioration in lung function and dyspnoea and in an increase in mild exacerbations and percentage of disturbed nights. This study clearly indicates a key role for ICS in the management of COPD as their discontinuation leads to disease deterioration, even under treatment with a LABA.


Related Articles

  • Review: Inhaled corticosteroids slow the progression of airflow limitation in COPD: COMMENTARY. Greenstone, Michael // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p57 

    Chronic obstructive pulmonary disease (COPD) is largely a disease of vulnerable smokers in whom the normal age-related decline in lung function is accelerated from a mean of 30 mL/y to 60 mL/y. Unlike asthma, the airflow obstruction and airway inflammation of COPD respond poorly to...

  • Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Vestbo, J.; Pauwels, R.; Anderson, J. A.; Jones, P.; Calverley, P. // Thorax;Apr2005, Vol. 60 Issue 4, p301 

    Background: Combined treatment with inhaled corticosteroids and long acting β2 agonists is approved for the treatment of chronic obstructive pulmonary disease (COPD), but little is known about the onset of effect of the combination. Methods: Data were used from 1465 patients with COPD entered...

  • A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Green, R. H.; Singh, S. J.; Williams, J.; Morgan, M. D. L. // Thorax;Feb2001, Vol. 56 Issue 2, p143 

    Background-puImonary rehabilitation programmes have been shown to improve both exercise tolerance and health status in patients with chronic obstructive pulmonary disease (COPD). The optimal duration for a pulmonary rehabilitation programme is, however, unknown. To assess whether the current...

  • Pulmonary Rehabilitation as Evaluated by Clinical Trials: An Overview. Riario-Sforza, Gian Galeazzo; Yacoub, Mona-Rita; Incorvaia, Cristoforo // Reviews on Recent Clinical Trials;May2010, Vol. 5 Issue 2, p76 

    During the 80' and the 90's, the role of pulmonary rehabilitation (PR) was still not clearly demonstrated. The following development of PR was mainly due to the increasing number of clinical studies providing proofs of its effectiveness, and convincing physicians, institutions, and regulatory...

  • Be bold and be sensible. Smith, Richard // BMJ: British Medical Journal (International Edition);9/6/2003, Vol. 327 Issue 7414, p510 

    Presents a preview of the September 6, 2003 issue of the "British Medical Journal" and discusses the character trait of boldness within the medical field. Warning from the Global Initiative on Chronic Obstructive Lung Disease against using opioids in managing patients with dyspnoea and chronic...

  • Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Sutherland E R; Allmers H; Ayas N T; Venn A J; Martin R J; Sutherland, E R; Allmers, H; Ayas, N T; Venn, A J; Martin, R J // Thorax;Nov2003, Vol. 58 Issue 11, p937 

    Background: Chronic obstructive pulmonary disease (COPD) is a syndrome of chronic progressive airflow limitation which occurs as a result of chronic inflammation of the airways and lung parenchyma. However, the role of inhaled corticosteroids in the treatment of COPD is...

  • Effects of Extra-Fine Inhaled and Oral Corticosteroids on Alveolar Nitric Oxide in COPD. Short, Philip; Williamson, Peter; Lipworth, Brian // Lung;Aug2012, Vol. 190 Issue 4, p395 

    Purpose: Alveolar nitric oxide (CA) has been suggested as a surrogate marker of distal airway inflammation in COPD. Coarse particle-inhaled corticosteroids (ICS) have been shown not to suppress CA. We evaluated whether extra-fine particle size ICS (HFA-BDP) or systemic oral corticosteroids could...

  • New study allays fear over inhaled steroids. Pedder, Cato // Pulse;11/10/2003, Vol. 63 Issue 45, p17 

    Reports on the results of the study examining the effects of inhaled corticosteroids in patients with asthma or chronic obstructive pulmonary disease (COPD) in the U.S. Tendency of COPD to lead to decrease in bone mineral density; Indication that the inhaled steroids slow lung function decline...

  • Daily corticosteroids were not better than as-needed corticosteroids in mild persistent asthma.  // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p60 

    This article presents information on a clinical study according to which daily corticosteroids were not better than as-needed corticosteroids in mild persistent asthma. This study explored that in patients with mild persistent asthma, how does intermittent, short-course corticosteroid treatment...


Read the Article


Sign out of this library

Other Topics